placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in FDA Approves Boehringer Ingelheims JASCAYD (nerandomilast) for IPF The U.S
This manuscript was prepared according to the International Society for Medical Publication Professionals Good Publication Practice for Communicating Company-Sponsored Medical Research: the GPP3 Guidelines
MARNYS L-carnitine+Vitamin B5 and the combination of its ingredients are widely used both for the recovery of athletes and people who closely monitor their energy-yielding metabolism
Xiao Y, Zou H, Li J, Song T, Lv W, Wang W, Wang Z, Tao S (2022) Impact of quorum sensing signaling molecules in gram-negative bacteria on host cells: current understanding and future perspectives
Inhalation and injection are alternative routes of administration